Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 26, 2020


TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results for fourth quarter and full-year 2019 and business update on Thursday, March 26, 2020. The Company's management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30 a.m. Eastern Time.

Conference Call Details:

Thursday, March 26, 2020, 8:30 a.m. Eastern Time (ET)

Domestic Dial-In Number: Toll-Free: (800) 816-3024

International Dial-In Number (857) 770-0106

Conference ID: 7695599

Webcast URL: https://edge.media-server.com/mmc/p/k9qym597

The conference call will also be broadcast live and available for replay for one month on the Company's website, https://tffpharma.com, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.

About TFF Pharmaceuticals' Thin Film Freezing technology platform

TFF Pharmaceuticals' Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at https://tffpharma.com.

###


These press releases may also interest you

at 08:44
The CandEs, a research and awards program focused on the elevation and promotion of a quality candidate experience and now part of ERE Media, today announced that Sense, an AI-powered Talent Engagement Platform that automates each stage of the hiring...

at 08:44
Nossa Imports partners with Minnesota-based beverage wholesaler New France Wine Company for distribution in Minnesota and North Dakota. Together, they will increase the visibility and availability of Nossa's Mexican and Portuguese wines in the...

at 08:42
Learning Tree International, a leading learning partner in skills training, certification and workforce development, today announced its all-new Professional Certificate Programs. By taking a unique approach, these programs assess and address the...

at 08:41
HighBridge Holdings, Inc. and Surly Brewing are pleased to announce they have entered into a contract for production of HighBridge Premium's THC infused beverages. Both parties are looking ahead to Q2, at which time Surly is expected to complete the...

at 08:40
Stratus Properties Inc. , a diversified real estate company with holdings, interests and operations in the Austin, Texas area and other select markets in Texas, today reported year ended December 31, 2023 results. Highlights and Recent...

at 08:36
Planet Home Lending, a premier national mortgage lender, servicer, and asset manager, has hired Andy Insua as Regional Sales Manager for the Southeast. With a diverse financial services background in consumer finance, commercial banking, and mortgage...



News published on and distributed by: